NTRK2 fusion
|
Solid Tumor
|
NTRK2 fusion
|
Solid Tumor
|
entrectinib Sensitive: A1 - Approval
ASCO 2022 - 3 days (NewA1)
|
entrectinib Sensitive: A1 - Approval
ASCO 2022 - 3 days - (New C3)
|
NTRK2 fusion
|
Breast Cancer
|
NTRK2 fusion
|
Breast Cancer
|
entrectinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks (NewA2)
|
entrectinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
|
NTRK2 fusion
|
Sarcoma
|
NTRK2 fusion
|
Sarcoma
|
larotrectinib Sensitive: A1 - Approval
|
larotrectinib Sensitive: A1 - Approval
|
NTRK2 fusion
|
Solid Tumor
|
NTRK2 fusion
|
Solid Tumor
|
larotrectinib Sensitive: A1 - Approval
|
larotrectinib Sensitive: A1 - Approval
|
NTRK2 fusion
|
Small Intestinal Carcinoma
|
NTRK2 fusion
|
Small Intestinal Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
GIST
|
NTRK2 fusion
|
GIST
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Peritoneal Cancer
|
NTRK2 fusion
|
Peritoneal Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Peritoneal Cancer
|
NTRK2 fusion
|
Peritoneal Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Fallopian Tube Cancer
|
NTRK2 fusion
|
Fallopian Tube Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Fallopian Tube Cancer
|
NTRK2 fusion
|
Fallopian Tube Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Sarcoma
|
NTRK2 fusion
|
Sarcoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Endometrial Cancer
|
NTRK2 fusion
|
Endometrial Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Papillary Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Papillary Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Small Intestinal Carcinoma
|
NTRK2 fusion
|
Small Intestinal Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Cancer
|
NTRK2 fusion
|
Pancreatic Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Cancer
|
NTRK2 fusion
|
Pancreatic Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
GIST
|
NTRK2 fusion
|
GIST
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
NSCLC
|
NTRK2 fusion
|
NSCLC
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Papillary Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Papillary Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Soft Tissue Sarcoma
|
NTRK2 fusion
|
Soft Tissue Sarcoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Esophageal Cancer
|
NTRK2 fusion
|
Esophageal Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Esophageal Cancer
|
NTRK2 fusion
|
Esophageal Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Cervical Cancer
|
NTRK2 fusion
|
Cervical Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Cervical Cancer
|
NTRK2 fusion
|
Cervical Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
NSCLC
|
NTRK2 fusion
|
NSCLC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Soft Tissue Sarcoma
|
NTRK2 fusion
|
Soft Tissue Sarcoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Biliary Tract Cancer
|
NTRK2 fusion
|
Biliary Tract Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Biliary Tract Cancer
|
NTRK2 fusion
|
Biliary Tract Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
CRC
|
NTRK2 fusion
|
CRC
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Breast Cancer
|
NTRK2 fusion
|
Breast Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Melanoma
|
NTRK2 fusion
|
Melanoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
HCC
|
NTRK2 fusion
|
HCC
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
HCC
|
NTRK2 fusion
|
HCC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Ovarian Cancer
|
NTRK2 fusion
|
Ovarian Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Ovarian Cancer
|
NTRK2 fusion
|
Ovarian Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
CRC
|
NTRK2 fusion
|
CRC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Anaplastic Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Anaplastic Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Anaplastic Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Anaplastic Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Salivary Gland Cancer
|
NTRK2 fusion
|
Salivary Gland Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Endometrial Cancer
|
NTRK2 fusion
|
Endometrial Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Salivary Gland Cancer
|
NTRK2 fusion
|
Salivary Gland Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Gastric Cancer
|
NTRK2 fusion
|
Gastric Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Gastric Cancer
|
NTRK2 fusion
|
Gastric Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Cutaneous Melanoma
|
NTRK2 fusion
|
Cutaneous Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Cutaneous Melanoma
|
NTRK2 fusion
|
Cutaneous Melanoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Glioma
|
NTRK2 fusion
|
Glioma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Rectal Cancer
|
NTRK2 fusion
|
Rectal Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Rectal Cancer
|
NTRK2 fusion
|
Rectal Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Glioma
|
NTRK2 fusion
|
Glioma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Vulvar Cancer
|
NTRK2 fusion
|
Vulvar Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Vulvar Cancer
|
NTRK2 fusion
|
Vulvar Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
GBM
|
NTRK2 fusion
|
GBM
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
GBM
|
NTRK2 fusion
|
GBM
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Solid Tumor
|
NTRK2 fusion
|
Solid Tumor
|
TPX-0005 Sensitive: B - Late Trials
|
TPX-0005 Sensitive: B - Late Trials
|
NTRK2 fusion
|
Solid Tumor
|
NTRK2 fusion
|
Solid Tumor
|
Trk inhibitor Sensitive: B - Late Trials
|
Trk inhibitor Sensitive: B - Late Trials
|
NTRK2 fusion
|
Lung Cancer
|
NTRK2 fusion
|
Lung Cancer
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Gastrointestinal Cancer
|
NTRK2 fusion
|
Gastrointestinal Cancer
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Small Cell Lung Cancer
|
NTRK2 fusion
|
Small Cell Lung Cancer
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Fibrosarcoma
|
NTRK2 fusion
|
Fibrosarcoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Cholangiocarcinoma
|
NTRK2 fusion
|
Cholangiocarcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Osteosarcoma
|
NTRK2 fusion
|
Osteosarcoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Thyroid Gland Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Carcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Cholangiocarcinoma
|
NTRK2 fusion
|
Cholangiocarcinoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Esophageal Squamous Cell Carcinoma
|
NTRK2 fusion
|
Esophageal Squamous Cell Carcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Colon Cancer
|
NTRK2 fusion
|
Colon Cancer
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
CNS Tumor
|
NTRK2 fusion
|
CNS Tumor
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
CRC
|
NTRK2 fusion
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
NTRK2 fusion
|
Glioma
|
NTRK2 fusion
|
Glioma
|
trametinib + entrectinib Sensitive: D – Preclinical
|
trametinib + entrectinib Sensitive: D – Preclinical
|
NTRK2 fusion
|
Glioma
|
NTRK2 fusion
|
Glioma
|
entrectinib + abemaciclib Sensitive: D – Preclinical
|
entrectinib + abemaciclib Sensitive: D – Preclinical
|
NTRK2 fusion
|
Solid Tumor
|
NTRK2 fusion
|
Solid Tumor
|
SIM1803-1A Sensitive: D – Preclinical
|
SIM1803-1A Sensitive: D – Preclinical
|